High Level of Viral Suppression and Low Switch Rate to Second-Line Antiretroviral Therapy among HIV-Infected Adult Patients Followed over Five Years: Retrospective Analysis of the DART Trial

• Cissy Kityo,

  Affiliation Joint Clinical Research Centre, Kampala, Uganda

  ⨯
• Diana M. Gibb,

  Affiliation MRC Clinical Trials Unit at UCL, London, United Kingdom

  ⨯
• Charles F. Gilks,

  Affiliation School of Population Health, University of Queensland, Australia

  ⨯
• Ruth L. Goodall,

  Affiliation MRC Clinical Trials Unit at UCL, London, United Kingdom

  ⨯
• Ivan Mambule,

  Affiliation Infectious Diseases Institute, Mulago, Uganda

  ⨯
• Pontiano Kaleebu,

  Affiliation MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda

  ⨯
• Deenan Pillay,

  Affiliation University College London, London, United Kingdom

  ⨯
• Ronnie Kasirye,

  Affiliation MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda

  ⨯
• Peter Mugyenyi,

  Affiliation Joint Clinical Research Centre, Kampala, Uganda

  ⨯
• A. Sarah Walker,

  Affiliation MRC Clinical Trials Unit at UCL, London, United Kingdom

  ⨯
• David T. Dunn ,

  * E-mail: d.dunn@ucl.ac.uk

  Affiliation MRC Clinical Trials Unit at UCL, London, United Kingdom

  ⨯
• on behalf of the DART Trial Team